



Starpharma and Nufarm Sign Crop Protection Agreement

Melbourne, Australia; 7 August 2012: Nufarm Limited (ASX:NUF), via its subsidiary Nufarm Australia Limited, and Starpharma Holdings Ltd (ASX:SPL; OTCQX:SPHRY) today announced the signing of an agreement under which the parties will apply Starpharma's Priostar[®] dendrimer technology to develop innovative crop protection formulations for Nufarm's product portfolio.

"We are very pleased to be working with Nufarm in this way," commented Dr Jackie Fairley, CEO Starpharma. "This agreement builds on previous collaboration between the companies and we are excited about the opportunity to work with Nufarm to develop innovative and improved products."

"This collaboration with Starpharma reflects Nufarm's renewed emphasis on technological innovation," said Lachlan McKinnon, Nufarm Australia's General Manager. "We are seeking innovative ways to differentiate our products so that growers are offered a wider range of control options tailored to their particular needs."

Starpharma's Priostar[®] dendrimer technology has wide applicability in the agrochemical sector. Through its own internal research program Starpharma has previously established that potential benefits of dendrimer to agrochemical formulators and end-user growers include:

- More concentrated formulations to reduce transport costs;
- Reduction in solvent loading;
- Improved overall activity; and
- Increased adhesion, to reduce losses due to rain run-off, and the need for multiple applications.

The terms of the agreement were not disclosed due to commercial confidentiality restrictions.

About Nufarm Limited

Nufarm Limited is one of the world's leading crop protection companies. Nufarm produces products to help farmers protect their crops against damage caused by weeds, pests and disease.

With manufacturing and marketing operations based in Australia, New Zealand, Asia, Europe and the Americas, Nufarm employs more than 3,000 people, all of whom make a vital contribution to the company's reputation for quality products, innovation and first class marketing and technical support.

Group Sales for FY2011 exceeded \$2billion.

Proudly based in Australia, Nufarm is listed on the Australian Stock Exchange (symbol NUF). Nufarm is the largest manufacturer of crop protection products in Australia.

About Starpharma Holdings Limited

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications.

Starpharma's underlying technology is built around dendrimers – a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical and other uses. Starpharma has three core development programs: VivaGel® portfolio, drug delivery and agrochemicals with the Company developing a number of products internally and others via commercial partnerships. In addition, products for diagnostics and laboratory reagents are already on market through licence arrangements with partners including Siemens Healthcare and Merck KGaA.

Starpharma's lead product is VivaGel® (SPL7013 Gel), a gel-based formulation of a proprietary dendrimer. VivaGel® is under clinical development for the treatment and prevention of bacterial vaginosis (BV) and also as a vaginal microbicide to prevent the transmission of sexually transmitted infections including HIV and genital herpes.

Starpharma has also signed separate licence agreements with Ansell Limited (ASX:ANN) and Okamoto Industries Inc (Tokyo Stock Exchange) to market a value-added, VivaGel®-coated condom. Ansell manufactures and sells leading condom brands worldwide, including Lifestyles®, ZERO® and SKYN®. Okamoto is the market leader for condoms sold in Japan, the world's second largest condom market.

In the wider pharmaceutical and life science fields, Starpharma has both partnered and internal programs in Drug Delivery. Most recently Starpharma announced pre-clinical results in its Docetaxel (Taxotere®) program demonstrating significant improvements in that agent's anticancer efficacy and the enhancement of solubility offering potential safety benefits as well. The company is also exploring dendrimer opportunities in agrochemicals in a series of industry partnerships as well as with internal programs including an enhanced version of glyphosate (the active ingredient in Roundup®).

Starpharma's headquarters and research facilities are located in Melbourne, Australia

FOR FURTHER INFORMATION

Media:

Buchan Consulting

Rebecca Wilson

Mob: +61 417 382 391

rwilson@buchanwe.com.au

Haley Price

Mob: +61 423 139 163

hprice@buchanwe.com.au

Starpharma:

Dr Jackie Fairley, Chief Executive Officer

+61 3 8532 2704

Ben Rogers, Company Secretary

ben.rogers@starpharma.com

www.starpharma.com

Nufarm:

Megan Beange

Marketing Communications Manager

Nufarm Australia

Phone: 03 9282 1578

Mobile: 0408 944 806

Email: megan.beange@au.nufarm.com

Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.